Meletios A. Dimopoulos, MD is Professor and Chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, where he obtained his medical degree in 1985. Dr.Dimpoulos has also completed residency in internal medicine at the Royal Victoria Hospital, McGill University, Montreal, Canada and a fellowship in hematology/oncology at the University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA. Dr. Dimopoulos has authored more than 1060 publications (July 2020) in peer-reviewed journals, as well as numerous abstracts and several textbook chapters primarily focusing on plasma cell dyscrasias and genitourinary and gynecologic cancers. He is on several editorial boards as well as being an Associate Editor of the European Journal of Internal Medicine (2001-2007) and Current Hematologic Malignancy Reports.
He serves on the Scientific Advisory Boards of the International Myeloma Foundation, of the International Waldenstrom’s Macroglobulinemia Foundation and he is member of the Board of the European Myeloma Network and International Myeloma Society. Currently, he is the chairman of the Greek Myeloma Study Group and of the Balkan Myeloma Study Group. Dr. Dimopoulos has won several awards including the Robert A. Kyle Award for outstanding contributions to Waldenstrom’s macroglobulinemia, the CoMy Excellence Award, the Robert Kyle Life Achievement Award and the MD Anderson Distinguished Alumnus Award.
We understand that when you make a donation, you want to know exactly what happens to your money. We aim to be clear and transparent when it comes to using your contributions in our mission to fight cancer.Your donations not only help us to empower the cancer patient community and make a positive difference to healthcare, treatment and accessibility, but also enable us to:
ensure our members are engaged and feel part of an active community through information, training, unique resources, tools, opportunities and networking at a national and European level
legitimise our position of cancer patient representatives before decision-makers
build a reputation as a cancer patient expert within the scientific community
find partners sharing the same vision, values and goals to work together on projects
get the media’s attention in order to publish and disseminate our messages